Australia is continuing to make progress against cancer, but the regional and remote disadvantage remains

I

n Australia, as in other high-income countries, mortality rates from cancer have been decreasing since the 1990s.1 This is largely the result of declining smoking rates in men, combined with earlier diagnosis and better treatment across a range of cancer types for both men and women.2

Despite overall progress, disparities for defined groups can persist or even increase.3 Historically, a well known disparity in Australia has been the higher cancer death rates among the 6 million people (27% of the Australian population) who live in regional and remote areas (non-metropolitan cities and towns plus rural and remote localities).4 Our aim was to assess whether the disadvantage in cancer deaths rates among regional and remote Australians has reduced over the past decade (from 1 January 2001 to 31 December 2010).

Abstract

Objective: To measure progress, over the past decade, in reducing the disadvantage in cancer death rates among people living in regional and remote areas of Australia.

Design: Analysis of routinely collected death certificate and corresponding population data from the Australian Bureau of Statistics.

Setting: Population-based, Australia-wide comparison of mortality rates in regional and remote areas compared with metropolitan areas from 1 January 2001 to 31 December 2010.

Main outcome measures: Absolute and relative excess of cancer deaths in regional and remote areas.

Results: The number of excess cancer deaths in regional and remote areas from 2001 to 2010 was 8878 (95% CI, 8187–9572). For men, the age-standardised mortality ratios (comparing regional and remote areas with metropolitan areas) showed no evidence of improvement, from 1.08 in 1997–2000 to 1.11 in 2006–2010. For women, they increased from 1.01 in 1997–2000 to 1.07 in 2006–2010. The age-standardised cancer death rate in regional and remote areas (annual percentage change [APC], −0.6%; 95% CI, −0.8% to −0.4%) is decreasing more slowly than in metropolitan areas (APC, −1.1%; 95% CI, −1.3% to −1.0%).

Conclusions: The regional and remote disadvantage for cancer deaths has been recognised as a problem for more than two decades, yet we have made little progress. This is not surprising — we have not invested in research into solutions. The benefits of laboratory and clinical research to identify innovative cancer treatments will not be fully realised across the entire Australian population unless we also invest in health systems and policy research.

Methods

The Australian Bureau of Statistics (ABS) provided data on cancer deaths and estimated resident populations by 5-year age groups and sex. The death data comprised numbers for all cancers combined, as well as for seven common causes of cancer death: lung cancer, colorectal cancer, breast cancer, prostate cancer, melanoma, oesophageal cancer and pancreatic cancer. A cancer death was defined as one for which the underlying cause of death was documented on the death certificate as cancer. Usual residence was classified as “metropolitan” or “regional and remote” based on the ABS Australian Standard Geographic Classification (ASGC).5 More specifically, “metropolitan” residence was defined as residence in one of the following cities: Sydney or Newcastle, New South Wales; Melbourne or Geelong, Victoria; Brisbane or Gold Coast, Queensland; Perth, Western Australia; Adelaide, South Australia; Hobart, Tasmania; Canberra, Australian Capital Territory and Darwin, Northern Territory. All remaining areas were categorised as “regional and remote”.

We calculated two arithmetic measures: the number of cancer deaths averted across all of Australia and excess cancer deaths in regional areas.

The first measure — the number of cancer deaths averted (as a result of the reduction in death rates over time) across all of Australia — was calculated as the difference between the expected number of deaths if the death rates had not decreased and the number of deaths actually observed. The expected number of deaths was obtained by applying the 5-year age- and sex-specific mortality rates for 1997–2000 to the corresponding age- and sex-specific populations for each subsequent year through to 2010.

The second measure — excess cancer deaths in regional and remote areas — was calculated by applying 5-year age- and sex-specific mortality rates for metropolitan areas for a particular year to the corresponding age- and sex-specific populations for regional and remote areas for the same year.

We also calculated two relative measures: annual percentage change (APC) and age-standardised mortality ratios (SMRs).

Estimates of the APC, overall and separately for metropolitan and regional and remote areas, were calculated using Poisson regression models with the year fitted as a linear term and 5-year age groups fitted as indicator variables.

SMRs for three separate time periods (1997–2000, 2001–2005 and 2006–2010) were calculated by applying age- and sex-specific death rates for the metropolitan population for the relevant time period to the age- and sex-specific populations in regional and remote areas. Confidence intervals for all measures were obtained under the assumption that observed numbers of deaths follow a Poisson distribution.
Results

The percentage of Australians living in regional and remote areas remained stable at 27%–28% over the 10 years from 2001 to 2010. The regional and remote population is slightly older than the metropolitan population, and both populations became slightly older over the study period (in 2001, the percentage of population older than 70 years was 9.4% in regional and remote areas and 8.9% in metropolitan areas, and in 2010, this percentage was 10.5% in regional and remote areas and 9.9% in metropolitan areas).

For men, the SMRs (comparing regional and remote areas with metropolitan areas) showed no evidence of improvement, from 1.08 in 1997–2000 to 1.11 in 2006–2010. For women, they increased from 1.01 in 1997–2000 to 1.07 in 2006–2010 (Box 1).

The number of excess cancer deaths in regional and remote areas between 2001 and 2010 was 6092 for men (95% CI, 5564–6622) and 2786 for women (95% CI, 2340–3234), giving a total of 8878 excess cancer deaths (95% CI, 8187–9572) (Box 2A). The largest numbers of excess deaths were for cancers of the lung, prostate, oesophagus and colorectum, and melanoma (Box 1).

In the face of the continuing excess of deaths in regional and remote areas, progress against cancer is continuing across all of Australia, as a whole. The number of cancer deaths averted in Australia in the 10 years from 2001 to 2010 (based on age- and sex-specific death rates for 1997–2000), was 31 557 (95% CI, 30 315–32 796) (Box 2B). More deaths were averted in men than in women because the number of lung cancer deaths among women actually increased over the 10 years (Box 3). This mainly reflects the later peak and later subsequent decline in smoking rates among women. Between 2001 and 2010, the APC in cancer deaths across all of Australia was – 1.0% (95% CI, 1.1% to – 0.9%), but the decrease was larger in metropolitan areas (– 1.1%; 95% CI, – 1.3% to – 1.0%) than in regional and remote areas (– 0.6%; 95% CI, – 0.8% to – 0.4%).

Discussion

The results presented here show that in the past decade good progress has been made in decreasing cancer deaths across all of Australia. However, the results show little, if any, progress in reducing regional and remote disadvantage. During the decade 2001–2010, there were about 9000 excess cancer deaths in regional and remote areas. Also, the decrease in death rates has been slower in regional and remote areas (APC, – 0.6%) compared with metropolitan areas (APC, 1.1%).

Causes of excess cancer deaths in regional and remote Australia

These can be divided into upstream and downstream factors. Upstream factors include higher proportions of Indigenous people and greater economic disadvantage associated with some regional and remote locations. Downstream factors include a higher prevalence of cancer risk factors, such as smoking, sun exposure and obesity, less cancer screening, delays in seeking medical attention or delays in diagnosis, higher prevalence of comorbid conditions, and treatment disparities. Upstream factors mainly exert their effect on mortality through downstream factors, although they can also exert an independent effect; for example, Indigenous cancer patients might have specific difficulties in navigating the health system or in coming to terms with the risks and benefits of cancer treatment.

Our analyses showed that there were 750 excess deaths due to colorectal cancer. Contributing factors
could include less screening with faecal occult blood tests or colonoscopies, resulting in later diagnosis, or higher prevalence of risk factors such as obesity. A further factor could be that metropolitan patients are more likely to be treated in high-volume specialist centres, which have been shown both in Australia and overseas to reduce short-term and long-term mortality after complex cancer surgery. Differential rates of chemotheray use might also play a role. Volume-outcome associations might also be contributing to the 842 excess deaths for oesophageal cancer.

Notably there were no excess deaths for breast cancer. This shows that the problem is not intractable: organisation of diagnosis and treatment services for breast cancer might serve as a learning model for other types of cancers.

**Need for evidence-based solutions**

We posit that at least part of the reason for the lack of progress is the lack of investment in research about the clinical effectiveness and cost-effectiveness of possible solutions to diagnosis and treatment disparities (health systems and policy research). For example, the only evidence about the effectiveness of regional cancer centres shows that if capacity is increased, patients (who would have otherwise had to travel for treatment) receive treatment locally. This surrogate outcome does not provide convincing evidence about the effect of regional cancer centres on quality of life or survival, and we do not know whether regional cancer centres are a more cost-effective way of achieving health gains than, for example, increasing funding for patient travel and accommodation.

More generally, there is no evidence to guide public investment in solutions to diagnosis and treatment disparities, because we have under-invested in health systems and policy research (as have other countries). Evidence synthesis and economic decision analysis are not possible because there is no evidence to synthesise. In 2010, the federal government announced an investment of $560 million over 5 years in regional cancer centres. This will hopefully result in significant health gains. However, an important contrast is that, for a new cancer pharmaceutical, convincing evidence is required of both comparative clinical effectiveness and comparative cost-effectiveness, before the pharmaceutical can be subsidised with taxpayer dollars. Hence, investment is needed, not only in actual evaluations of health systems and policy interventions, but also in the development of appropriate methods of evaluation.

The regional and remote excess of cancer deaths has been recognised as a problem for at least two decades. Yet we have made little progress. Research to guide service planning and budget decisions is not as prestigious as laboratory and clinical research to identify and test innovative diagnostic tests and treatments for cancer. However, such research is needed if all of the Australian community are to benefit from laboratory and clinical advances.

**Competing interests**: No relevant disclosures.
Take the guesswork out of monitoring wheeze

A recent survey shows that two thirds of Australians with asthma do not monitor their condition. This can make it difficult to manage asthma effectively.

AirSonea is the world’s first handheld device that turns a patient’s smartphone into a portable wheeze monitor. When combined with the AsthmaSense smartphone app, AirSonea provides patients with a comprehensive monitoring system to record and track wheeze symptoms, events, medication usage, and environmental factors.

AirSonea is listed on the Australian Register of Therapeutic Goods, and when used regularly by your patient, gives you an accurate picture of recent asthma events to review at their next visit.

Find out how you and your patients can better monitor wheeze. airsonaea.com.au